Racial, Ethnic, and Insurance-Based Disparities Upon Initiation of Anti–Vascular Endothelial Growth Factor Therapy for Diabetic Macular Edema in the US

Research Lead:

Nisha A. Malhotra, MPH Tyler E. Greenlee, DO Amogh I. Iyer, BS Thais F. Conti, MD Andrew X. Chen, BSE Rishi P. Singh, MD

Purpose

This study characterizes the association of risk factors including race, ethnicity, and insurance status with presenting visual acuity (VA) and diabetic retinopathy (DR) severity in patients initiating treatment with anti–vascular endothelial growth factor (VEGF) therapy for diabetic macular edema (DME).

Design

Retrospective, cross-sectional study.

Participants

The Academy Intelligent Research in Sight (IRIS) Registry database was queried for patients who initiated anti-VEGF injection treatment for DME between 2012 and 2020 (n = 203 707).

Methods

Multivariate regression analyses were conducted to understand how race, ethnicity, insurance status, and geographic location were associated with baseline features.

Main Outcome Measures

Visual acuity and DR severity.

Results

Patients on Medicare and private insurance presented with higher baseline VA compared with patients on Medicaid (median of 2.31 and 4.17 greater Early Treatment Diabetic Retinopathy Scale [ETDRS] letters, respectively P < 0.01). White and non-Hispanic patients presented with better VA compared with their counterparts (median of 0.68 and 2.53 greater ETDRS letters, respectively; P < 0.01). Black and Hispanic patients presented with a worse baseline DR severity compared with White and non-Hispanic patients (odds ratio, 1.23 and 1.71, respectively; P < 0.01).

Conclusions

There are ethnic and insurance-based disparities in VA and disease severity upon initiation of anti-VEGF therapy for DME treatment. Public health initiatives could improve timely initiation of treatment.

Abbreviations and Acronyms:

DM (diabetes mellitus), DME (diabetic macular edema), DR (diabetic retinopathy), ETDRS (Early Treatment Diabetic Retinopathy Study), HbA1c (glycated hemoglobin), IRIS (Intelligent Research in Sight), NPDR (nonproliferative diabetic retinopathy), OR (odds ratio), PDR (proliferative diabetic retinopathy), VA (visual acuity), VEGF (vascular endothelial growth factor)

Ab Interno Minimally Invasive Glaucoma Surgery Combined with Cataract Surgery and Cataract Surgery Alone: IRIS®️ Registry Study

April 7, 2024
Read More

Comparison of Methods of Clinical Trial Emulation Utilizing Data from the Comparison of AMD Treatment Trial (CATT) and the IRISⓇ Registry

April 3, 2024
Read More

Multi-registry analysis of patients with multiple sclerosis and neuromyelitis optica to improve capture of demographic data and compare visual outcomes

February 11, 2024
Read More

Vitreoretinal Specialist Use of Ancillary Testing: An IRIS®️ Registry Analysis

October 20, 2023
Read More

Evaluation of treatment and switching patterns for Dry Eye Disease medications using linked EHR and Claims data

October 19, 2023
Read More

Vitreoretinal Specialist Use of Ancillary Testing: An IRIS® Registry Analysis

October 17, 2023
Read More

Impact of Anti-VEGF Treatment and Patient Characteristics on Vision Outcomes in nAMD: Up to 6-Year Analysis of the AAO IRIS® Registry

October 10, 2023
Read More

24 Month Real-World Study of Intraocular Pressure and Medication Reduction in Ab Interno Microinvasive Glaucoma Surgery Combined with Cataract Surgery Compared with Cataract Surgery Only: An IRIS® Registry Study

September 20, 2023
Read More

Enhancing assessment of demographics and visual outcomes in MS and NMO patients through combination of neurology and ophthalmology based registries

July 31, 2023
Read More
Qdata

Talk to a Qdata Expert

Take a minute to submit your contact information and one of our team members will reach out to you.